{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-077895","form_type":"8-K","ticker":"SYBX","cik":"0001527599","company_name":"SYNLOGIC, INC.","filed_at":"2022-03-17T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.860824+00:00","generated_at":"2026-06-26T21:58:57.725498+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Synlogic Q4 2021 net loss $15.1M; cash $136.6M; PKU Phase 3 on track for H2 2022","bullets":["Q4 2021 net loss $15.1M ($0.21/share) vs $14.6M ($0.39/share) in Q4 2020; FY 2021 net loss $60.6M ($1.09/share).","Cash, equivalents & marketable securities $136.6M at Dec 31, 2021; projected runway into 2024.","PKU program: Phase 2 SynPheny-1 data expected H1 2022; Phase 3 trial initiation planned H2 2022.","Appointed Michael Jensen as CFO in March 2022; he was formerly CFO of Intrinsic Therapeutics.","HCU candidate SYNB1353 IND submission and Phase 1 healthy volunteer data expected H2 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-077895","json":"https://secwatch.observer/filing/0001193125-22-077895.json","markdown":"https://secwatch.observer/filing/0001193125-22-077895.md","text":"https://secwatch.observer/filing/0001193125-22-077895.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/0001193125-22-077895-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1527599/000119312522077895/d284910d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:58:57.725498+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}